Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Temsirolimus in Advanced Renal Cancer
NCT01264341Phase 2Terminated
- Sponsor
- HeCOG
- Start
- Dec 2010
- Primary completion
- Jul 2015
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and temsirolimus in renal cell carcinoma (RCC), sponsored by HeCOG. Primary endpoint: 6-month Progression Free Survival. Started Dec 2010; status: terminated.
02
Drugs
bevacizumabtemsirolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01264341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01264341.